Auvelity as a Potential Treatment for Alzheimer’s Disease

Alzheimer’s disease is the most common form of dementia affecting older adults. also shares a significant association with Major Depressive Disorder. Glutamatergic excitotoxicity via NMDA receptors believed to be key mechanism underlying neurodegeneration in Disease. Blockade by antagonists like Memantine appears inhibit glutamatergic excitotoxicity. increases dopaminergic activation through agonism sigma-1 receptors. The combination these two mechanisms underlie Memantine’s improvements memory, cognition and general functioning AD patients. Auvelity was recently approved FDA for treatment Disorder Auvelity’s relevant action its blockade consequent antagonism neurotransmitter pathway, receptor. Because medications employ same action, it hypothesized that might potential medical reducing symptoms disease.